125 related articles for article (PubMed ID: 25931139)
21. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
22. Importance of target-mediated drug disposition for small molecules.
Smith DA; van Waterschoot RAB; Parrott NJ; Olivares-Morales A; Lavé T; Rowland M
Drug Discov Today; 2018 Dec; 23(12):2023-2030. PubMed ID: 29928850
[TBL] [Abstract][Full Text] [Related]
23. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Mager DE; Krzyzanski W
Pharm Res; 2005 Oct; 22(10):1589-96. PubMed ID: 16180117
[TBL] [Abstract][Full Text] [Related]
24. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
[TBL] [Abstract][Full Text] [Related]
25. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
[TBL] [Abstract][Full Text] [Related]
26. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
[TBL] [Abstract][Full Text] [Related]
27. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Marathe A; Krzyzanski W; Mager DE
J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
[TBL] [Abstract][Full Text] [Related]
28. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
29. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
30. Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.
Sorensen B; Winn M; Rohde J; Shuai Q; Wang J; Fung S; Monzon K; Chiou W; Stolarik D; Imade H; Pan L; Deng X; Chovan L; Longenecker K; Judge R; Qin W; Brune M; Camp H; Frevert EU; Jacobson P; Link JT
Bioorg Med Chem Lett; 2007 Jan; 17(2):527-32. PubMed ID: 17070044
[TBL] [Abstract][Full Text] [Related]
31. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
[TBL] [Abstract][Full Text] [Related]
32. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
Byun JH; Jeon HS; Yun HY; Kim JK
PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
[TBL] [Abstract][Full Text] [Related]
33. Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.
Sorensen B; Rohde J; Wang J; Fung S; Monzon K; Chiou W; Pan L; Deng X; Stolarik D; Frevert EU; Jacobson P; Link JT
Bioorg Med Chem Lett; 2006 Dec; 16(23):5958-62. PubMed ID: 16996734
[TBL] [Abstract][Full Text] [Related]
34. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
35. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
[TBL] [Abstract][Full Text] [Related]
37. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
38. A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.
Dua P; Hawkins E; van der Graaf PH
CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):324-37. PubMed ID: 26225261
[TBL] [Abstract][Full Text] [Related]
39. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
[TBL] [Abstract][Full Text] [Related]
40. Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
Patel JR; Shuai Q; Dinges J; Winn M; Pliushchev M; Fung S; Monzon K; Chiou W; Wang J; Pan L; Wagaw S; Engstrom K; Kerdesky FA; Longenecker K; Judge R; Qin W; Imade HM; Stolarik D; Beno DW; Brune M; Chovan LE; Sham HL; Jacobson P; Link JT
Bioorg Med Chem Lett; 2007 Feb; 17(3):750-5. PubMed ID: 17110106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
